Kelonia Therapeutics, Inc. — Form D
Kelonia Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2022-04-29. The offering totals $50.3M, of which $50.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-04-29
- Form: D
- Accession: 0001925270-22-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.3M
- Amount sold: $50.3M
- Investors: 8
- Date of first sale: 2022-04-14
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-443816
Issuer
- Name: Kelonia Therapeutics, Inc.
- CIK: 0001925270
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 700 MAIN STREET, CAMBRIDGE, MA, 02139
- Phone: 503-703-1299
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Michael Birnbaum | Director | Cambridge, MA |
| Michael Fischbach | Director | Cambridge, MA |
| Kevin Friedman | Director | Cambridge, MA |
| Bob More | Director | Venice, CA |
| Bryan Roberts | Director | Boulder, CO |
| Kevin Friedman | Executive Officer | Cambridge, MA |
More